Background: Successful CTO treatment is able to increase left ventricular function, exercise capacity and reduction of mortality. Up to date no adequate information on stent strut endothelialisation after CTO treatment is available. In particular, the duration of dual antiplatelet therapy (DAPT) remains an issue of debate. Following CTO treatment, patients are at risk for restenosis as well as stent thrombosis. DAPT is able to sufficient reduce frequency of stent thrombosis, but keeps an increased risk of major bleeding in case of unnecessarily prolonged ingestion. Intracoronary optical coherence tomography (OCT) is a novel invasive method, which is able to precisely analyse stent strut endothelialisation. We tested the hypothesis, that OCT detects delayed endothelialisation after CTO treatment compared to non-CTO PCI. Methods: We performed diagnostic OCT measurements following successful CTO treatment (n ¼ 22) as well as non-CTO DES PCI of complex lesions (n ¼ 29). All Patients had been treated with 2nd generation DES. Mean time point of OCT analysis was 7.8 months and 6.5 months, respectively (p ¼ 0.83). Results: The two groups were well matched and similar concerning characteristics. Stent struts (in total n ¼ 13629) were analysed and classified by OCT according to previously described methods (CTO recanalization vs. non-CTO DES; mean +/-SEM): covered struts: 81.65 +/-2.9% vs. 97.34 +/-0.78%, p<0.0001; protruding/uncovered struts: 10.1 +/-1.7% vs. 1.4 +/-0.4%, p<0.0001; malapposed/uncovered struts: 7.9 +/-2.0 % vs. 1.3 +/-0.5 %, p<0.001. We performed subgroup analysis concerning CTO recanalization by antegrade vs. retrograde approach as well as subintimal tracking vs. non-subintimal tracking methods. No significant differences were found concerning subgroup analysis. No MACE events were detected in this series. Conclusions: Here we describe delayed stent endothelialisation after CTO treatment. Our results suggest an urgent need to extend the DAPT after CTO treatment to reduce the risk of late stent thrombosis. OCT allows interventional cardiologists to safe and precisely perform follow-up examinations in patients after CTO recanalization with the ability of individualise the duration of DAPT.
Background: Second-generation drug-eluting stents (DES) have reduced the occurrence of target vessel revascularisation (TVR) and stent thrombosis compared to first-generation DES but the clinical impact in chronic total occlusion (CTO) is poorly described. We aimed to compare long-term outcome after 1st and 2nd-generation DES in patients with CTO. Methods: Of 1,343 consecutive Patients who underwent PCI for CTO between 2004 and 2012, long term outcome was evaluated after successful DES implantation. Major adverse cardiac events (MACE) including cardiac death, target vessel revascularisation (TVR) and myocardial infarction (MI) were compared between patients treated with 1st (sirolimus and paclitaxel) and 2nd -generation DES (everolimus, zotarolimus and biolimus). Results: Procedural success was achieved in 1000 (74.4 %) patients of which 943 (70.2%) received at least one stent. DES were implanted in 873 patients (65%) who defined the study population.Patients treated with 1st generation DES (583 patients, 66.9% of the whole population) had a higher rate of current smoking (28% vs. 20% p¼0.007), were more frequently treated for left anterior descending CTO (37% vs. 29% p¼0.018) and had shorter stent length (46 AE 25 vs. 51 AE 25 mm, p¼) compared to patients treated by 2nd generation DES. Age, gender, diabetes, and LVEF were similar between groups. Median follow-up was at 4.1 years (IQR: 2.4-6.5 years). Patients treated 2nd generation DES had lower MACE rate compared to 1st-generation DES (12.7% vs. 21.3%, respectively, p¼0.003). The decrease in MACE rate was driven by lower TVR (8.7%, vs. 13.4%, respectively p¼0.04) whereas cardiac death and MI were similar between groups (p¼0.32 and p¼0.15, respectively). Cumulative event rates by Kaplan-Meier analysis showed lower incidence of TVR among patients treated by 2nd generation stent (p Log Rank ¼0.02). Background: PCI of chronic total occlusion (CTO) has become more and more aggressive during the last decade, especially because of frequent use of hydrophilic, hard and stiff wires, which have increased the rate of success. Indeed, the incidence and clinical consequences of cardiac tamponade in contemporary practice remain relatively unknown.
Conclusions
Methods: Between October 2003 and June 2010, a total of 1509 consecutive patients were treated by PCI for a CTO defined as the presence of TIMI 0 flow within an occluded arterial segment of greater than 3 months standing. The population characteristics were compared regarding the presence of per and post-procedural tamponade. Results: A cardiac tamponade occurred in 18/1509 patients (1.2%) . As opposed to patients with a tamponade-free procedure, patients who have experienced cardiac tamponade were older (68.6AE10.34 vs. 63.4AE11.29, p¼0.03) and had similar risk factors (diabetes in 27% and dyslipidemia in 64%). Cardiac tamponade occurred more frequently in experienced operators reflecting more complex procedures. Absence of visible stump was associated with higher rate of cardiac tamponade (50% vs. 24.8% for patients without tamponade, p¼0.02). There were no differences regarding other angiographic characteristics between the two groups (calcifications, proximal tortuosities, lesion length). The use of a tornus device and a retrograde approach were associated with higher rates of cardiac tamponade (0.17vs 0.02 p¼0.01, and 0.28vs 0.01 p¼0.02, respectively). Procedural duration was longer in patients in whom a cardiac tamponade occurred (124AE24 minutes, vs. 92AE37 minutes, p¼0.01) and success rate was equal (0.77 vs 0.70., p¼0.61, respectively). Importantly, in-hospital stay was longer (7.2AE3.6, vs. 3.1AE3, p<0.0001, respectively), and rate of in-hospital death was higher among patients who have experienced cardiac tamponade compared to those without per and post-procedural tamponade (11% vs. 1%, p¼0.01, respectively). Conclusions: Cardiac tamponade occurred in 1.2% of a broad population of consecutive patients treated by PCI for chronic total coronary occlusion. Absence of visible stump and use of aggressive devices and strategies were more frequently associate.
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Myocardial Background: Percutaneous recanalization of chronic total coronary occlusions (CTO) tends to show a positive effect on LV remodeling and ejection fraction (EF). Nevertheless, its effects on global cardiac functions are yet to be fully understood. Myocardial performance index (MPI) is likely to be more effective for analysis of global cardiac dysfunction than systolic and diastolic measures alone. The aim of this study was to evaluate the effects of recanalization of CTO on global cardiac functions by using MPI. Methods: We evaluated 25 patients (20 men, mean age 57.5AE14.1 years) who had ischemia on myocardial perfusion imaging and underwent successful percutaneous coronary intervention of right coronary artery (RCA) CTO. All patients underwent transthoracic echocardiography before (basal), 24 hours after (early) and at third months (late) of successful PCI. The MPI was calculated by using pulse wave tissue Doppler (TD) echocardiography. Results: There was no difference between basal, early and late left ventricular ejection fraction values (53.5AE10.2, 53.3AE9.5, 53.3AE11.2, respectively). The MPI at third month was significantly increased compared to the basal and early MPI (0.61AE0.09 vs. 0.53AE0.07; p <0.001 and 0.60AE0.08 vs. 0.53AE0.07; p<0.001, respectively). On the other hand, there was no significant difference between basal and early MPI (0.61AE0.09 vs. 0.60AE0.08; p¼0.84, respectively). Also, TD MPI within 3 months was significantly increased when compared to others (0.58AE0.9 vs. 0.53AE0.8; p¼0.003, 0.57AE0.07 vs. 0.53AE0.8; p<0.001, respectively for TD MPI septal and 0.59AE0.08 vs. 0.51AE0.07; p<0.001, 0.58AE0.08 vs. 0.51AE0.07; p<0.001, respectively for TD MPI lateral).
Conclusions:
In this study, we have shown that successful recanalization of CTO results in increased MPI-indicated global cardiac functions within 3 months, while the EF values remain unchanged.
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Drug eluting stents with bioresorbable polymershort and long term clinical outcomes in the treatment of CTO lesions Alexander G. Osiev 1 , Bernard Chevalier 2 , Thomas Hovasse 2 , Andres Iñiguez 3 , Marie-Claude Morice 4 , Jawed Polad 5 , Antonio Serra 6 Other techniques used included CTO dedicated wires, OTW balloon, microcatheter, rotational atherectomy and cutting balloon. Mean diameter stenosis before procedure was 91AE16% and TIMI 0 and 1were recorded in 59% of the all lesions treated (not all were CTO). Mean fluoro time was 37AE38 minutes and contrast volume was 276AE135 mL. After procedure mean diameter stenosis was 7AE17% and TIMI 0 and 1 were observed in only 3% of the lesions. Up to 1-month, there was 1death, 3 MIs (0.6%) and no TLR. Four CD (1.2%) and three TLRs (0.9%) were reported up to one year follow-up bringing the total TLF rate to 2.4%. Target vessels non-target lesion revascularizations were performed in 2 patients (0.6%). Only one probable subacute stent thrombosis (0.2%) occurred. In the cohort of patients followed at 3-year, 3 patients suffered a CD (3.1%), 1 had an MI (1.0%), 3 underwent TLR (3.1%) and TLF rate was 6.2% with no late or very late stent thrombosis.
Conclusions: Treatment of CTO with Nobori DES showed excellent outcomes. Particularly appealing is that stent thrombosis was very rare despite the multiple overlapping stents. The low rate of procedural complications and adverse events up to 3 years suggests that this stent is a valuable treatment option for patients with CTO who are considered candidates for PCI.
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A Background: Up to 30% chronic total occlusions (CTO) cannot be revascularized by conventional angioplasty. Therapeutic enhancement of the antegrade collateral circulation may offer a novel solution. Previously, we investigated stimulation of endothelial cell (EC) angiogenesis via stabilized hypoxia inducible factor (HIF) utilizing two prolyl-hydroxylase inhibitors. We reported di-methyl oxalylglycine (DMOG) increased collateral neovascularization in a porcine CTO model and showed BIQ(FG-2216), trialled for use in man for alternative indications, induced a dosedependent pro-angiogenic response in primary human EC in vitro. We now report molecular mechanisms underlying the novel action of BIQ. Methods: Human umbilical vein ECs (HUVECs) were treated with 500mM BIQ for up to 24 hours. (100mM CoCl2 was used as a positive control for HIF-1a stabilization). Expression of HIF-1a protein from cell lysates was analyzed by Western blotting. Quantitative PCR was used to examine the expression of vascular endothelial cell growth factor (VEGF) mRNA from treated EC. Results: Stabilization of HIF-1a protein was demonstrated in EC after treatment with BIQ, along with a 1.45 fold increase in VEGF mRNA expression, after one hour of treatment ( Figure) .
Conclusions:
We have confirmed that BIQ(FG-2216) upregulates HIF-1a in EC and shown evidence for a mechanism involving the angiogenic factor VEGF; important if we plan to translate this therapy. On-going work includes the deployment of polymercoated BIQ eluting stents with in vitro and in vivo evaluation to develop an effective treatment for difficult CTOs in man.
TCT-381
The Safety And Efficacy Of The "Hybrid Approach" To Chronic Total Occlusions: Insights From A Contemporary Multicenter US Registry
